CCL

Összesen 3 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM045970
Első szerző:Bogousslavsky, Julien
Cím:The Mannheim Declaration of Stroke in Eastern Europe : accepted at the 13th European Stroke Conference, Mannheim-Heidelberg, Germany, May 12-15, 2004 / J. Bogousslavsky, M. G. Hennerici, M. Kaste, L. Csiba, M. Brainin, D. Bereczki, Z. Nagy, A. Czlonkowska, V. Demarin, J. Pascu, V. I. Skvortsova, E. Ehler
Dátum:2004
ISSN:1015-9770
Tárgyszavak:Orvostudományok Klinikai orvostudományok szerkesztőségi anyag
Megjelenés:Cerebrovascular Diseases. - 18 : 3 (2004), p. 248-248. -
További szerzők:Hennerici, M. Kaste, M. Csiba László (1952-) (neurológus, pszichiáter) Brainin, Michael Bereczki Dániel (1960-) (neurológus) Nagy Zoltán (1942-) (neurológus) Czlonkowska, A. Demarin, Vida Pascu, J. Skvortsova, Veronica I. Ehler, E.
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM046046
Első szerző:Diener, Hans-Christoph
Cím:Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH) : randomised, double-blind, placebo-controlled trial / Diener Hans-Christoph, Bogousslavsky Julien, Brass Lawrence M, Cimminiello Claudio, Csiba Laszlo, Kaste Markku, Leys Didier, Matias-Guiu Jordi, Rupprecht Hans-Jürgen, the MATCH Investigators
Dátum:2004
ISSN:0140-6736
Megjegyzések:Clopidogrel was superior to aspirin in patients with previous manifestations of atherothrombotic disease in the CAPRIE study and its benefit was amplified in some high-risk subgroups of patients. We aimed to assess whether addition of aspirin to clopidogrel could have a greater benefit than clopidogrel alone in prevention of vascular events with potentially higher bleeding risk. METHODS: We did a randomised, double-blind, placebo-controlled trial to compare aspirin (75 mg/day) with placebo in 7599 high-risk patients with recent ischaemic stroke or transient ischaemic attack and at least one additional vascular risk factor who were already receiving clopidogrel 75 mg/day. Duration of treatment and follow-up was 18 months. The primary endpoint was a composite of ischaemic stroke, myocardial infarction, vascular death, or rehospitalisation for acute ischaemia (including rehospitalisation for transient ischaemic attack, angina pectoris, or worsening of peripheral arterial disease). Analysis was by intention to treat, using logrank test and a Cox's proportional-hazards model. FINDINGS: 596 (15.7%) patients reached the primary endpoint in the group receiving aspirin and clopidogrel compared with 636 (16.7%) in the clopidogrel alone group (relative risk reduction 6.4%, [95% CI -4.6 to 16.3]; absolute risk reduction 1% [-0.6 to 2.7]). Life-threatening bleedings were higher in the group receiving aspirin and clopidogrel versus clopidogrel alone (96 [2.6%] vs 49 [1.3%]; absolute risk increase 1.3% [95% CI 0.6 to 1.9]). Major bleedings were also increased in the group receiving aspirin and clopidogrel but no difference was recorded in mortality. INTERPRETATION: Adding aspirin to clopidogrel in high-risk patients with recent ischaemic stroke or transient ischaemic attack is associated with a non-significant difference in reducing major vascular events. However, the risk of life-threatening or major bleeding is increased by the addition of aspirin.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Lancet. - 364 : 9431 (2004), p. 331-337. -
További szerzők:Bogousslavsky, Julien Brass, Lawrence M. Cimminiello, Claudio Csiba László (1952-) (neurológus, pszichiáter) Kaste, Markku Leys, Didier Matias-Guiu, Jordi Rupprecht, Hans-Jürgen the MATCH Investigators
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM029302
Első szerző:Diener, Hans-Christoph
Cím:Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH) : study design and baseline data / Diener, H. C., Bogousslavsky, J., Brass, L. M., Cimminiello, C., Csiba, L., Kaste, M., Leys, D., Matias Guiu, J., Rupprecht, H. J., the MATCH Investigators
Dátum:2004
ISSN:1015-9770
Megjegyzések:The CAPRIE study showed the superiority of clopidogrel over acetylsalicylic acid (ASA) for reducing the combined risk of major atherothrombotic events in patients with recent myocardial infarction (MI), recent ischaemic stroke (IS) or established peripheral arterial disease. The benefit of clopidogrel over ASA is amplified in high-risk patients. Proof of concept for the benefit of clopidogrel in addition to ASA in patients with coronary manifestations of atherothrombosis was provided by the CURE trial. METHODS: MATCH is a randomized, double-blind, placebo-controlled trial that compares clopidogrel and ASA versus clopidogrel alone in high-risk patients with recently symptomatic cerebrovascular disease. Eligible patients have experienced a transient ischaemic attack (TIA) or IS within the last 3 months and have evidence of at least 1 additional risk factor within the last 3 years (prior IS, MI, stable or unstable angina pectoris, diabetes or symptomatic peripheral arterial disease). Patients were randomized to receive ASA 75 mg once daily or placebo, with both groups receiving clopidogrel 75 mg once daily as part of standard therapy. The primary end point is the composite of IS, MI, vascular death and rehospitalization for an acute ischaemic event. The duration of treatment and follow-up is 18 months for each patient. RESULTS: Enrollment was completed in April 2002, with 7,599 patients randomized to receive the study medication. The mean age at randomization was 66 years, and the qualifying event was IS in 78.9% of patients and TIA in 21.1%. The baseline features of the study cohort indicate a population that is at a high risk for atherothrombotic recurrence. CONCLUSION: MATCH is a major ongoing trial that will provide important data on the benefit of clopidogrel and ASA compared with clopidogrel alone for reduction of vascular ischaemic events in patients with recent TIA or IS who are at high risk of atherothrombotic event recurrence.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Cerebrovascular Diseases. - 17 : 2-3 (2004), p. 253-261. -
További szerzők:Bogousslavsky, Julien Brass, Lawrence M. Cimminiello, Claudio Csiba László (1952-) (neurológus, pszichiáter) Kaste, Markku Leys, Didier Matias-Guiu, Jordi Rupprecht, Hans-Jürgen the MATCH Investigators
Internet cím:DOI
Borító:
Rekordok letöltése1